Joanne A Harrold Selected Research

Overweight

1/2019	Predictors of successful weight loss with relative maintenance of fat-free mass in individuals with overweight and obesity on an 8-week low-energy diet.
2/2008	The effect of Korean pine nut oil (PinnoThin) on food intake, feeding behaviour and appetite: a double-blind placebo-controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Joanne A Harrold Research Topics

Disease

12	Obesity 01/2012 - 10/2002
8	Weight Loss (Weight Reduction) 11/2021 - 03/2005
7	Body Weight (Weight, Body) 01/2021 - 04/2004
2	Overweight 01/2019 - 02/2008
2	Weight Gain 01/2008 - 06/2007
2	Feeding and Eating Disorders (Eating Disorder) 01/2007 - 10/2003
2	AIDS-Related Complex (ARC) 04/2004 - 03/2003
1	Alkaptonuria 05/2022
1	Cognitive Dysfunction 05/2022
1	COVID-19 01/2021
1	Type 2 Diabetes Mellitus (MODY) 01/2021
1	Insulin Resistance 01/2021
1	Pain (Aches) 03/2015
1	Starvation 04/2004
1	Hypoglycemia (Reactive Hypoglycemia) 04/2004
1	Hyperphagia (Overeating) 10/2002

Drug/Important Bio-Agent (IBA)

5	LeptinIBA 06/2007 - 10/2002
4	Insulin (Novolin)FDA Link 06/2007 - 10/2002
3	sibutramine (Meridia)FDA Link 01/2012 - 03/2005
3	5-HT2C Serotonin ReceptorIBA 01/2012 - 03/2005
3	lorcaserinIBA 01/2012 - 01/2007
3	Serotonin (5 Hydroxytryptamine)IBA 12/2011 - 03/2005
2	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 06/2007
2	Anti-Obesity Agents (Antiobesity Drugs)IBA 01/2012 - 01/2008
2	FenfluramineIBA 01/2012 - 03/2005
2	Pharmaceutical PreparationsIBA 12/2011 - 05/2010
2	5-Hydroxytryptophan (5 Hydroxytryptophan)IBA 01/2007 - 03/2005
2	LigandsIBA 01/2007 - 02/2006
2	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2007 - 03/2003
2	NeuropeptidesIBA 09/2004 - 04/2004
2	CannabinoidsIBA 10/2003 - 10/2002
1	nitisinone (Orfadin)FDA Link 05/2022
1	oxidized low density lipoproteinIBA 11/2021
1	SodiumIBA 01/2021
1	3-alpha-tropyl-2-(phenylthio)butyrateIBA 01/2021
1	dapagliflozinIBA 01/2021
1	Exenatide (Byetta)FDA Link 01/2021
1	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2021
1	LipidsIBA 01/2021
1	Lysophosphatidylcholines (Lysophosphatidylcholine)IBA 01/2021
1	Phosphatidylcholines (Phosphatidylcholine)IBA 01/2021
1	SphingomyelinsIBA 01/2021
1	Citric Acid (Citrate)FDA LinkGeneric 01/2021
1	SymportersIBA 01/2021
1	Proteins (Proteins, Gene)FDA Link 01/2019
1	GTP-Binding Proteins (G-Protein)IBA 01/2019
1	TesofensineIBA 12/2011
1	Triglycerides (Triacylglycerol)IBA 02/2008
1	Nonesterified Fatty Acids (NEFA)IBA 02/2008
1	Acetates (Acetic Acid Esters)FDA Link 01/2008
1	Biomarkers (Surrogate Marker)IBA 06/2007
1	Serotonin AgentsIBA 01/2007
1	Type 4 Melanocortin Receptor (Melanocortin-4 Receptor)IBA 02/2006
1	Melanocortin Receptors (Melanocortin Receptor)IBA 02/2006
1	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 03/2005
1	Fluoxetine (Prozac)FDA LinkGeneric 03/2005
1	melanin-concentrating hormone (melanin concentrating hormone)IBA 09/2004
1	Peptides (Polypeptides)IBA 04/2004
1	OrexinsIBA 04/2004
1	Anabolic AgentsIBA 04/2004
1	Neuropeptide YIBA 04/2004
1	alpha-MSHIBA 03/2003
1	Dimenhydrinate (DMH)FDA LinkGeneric 03/2003
1	beta-MSHIBA 03/2003
1	Guanosine 5'-O-(3-Thiotriphosphate)IBA 03/2003
1	mu Opioid Receptors (mu Opioid Receptor)IBA 10/2002
1	Opioid Analgesics (Opioids)IBA 10/2002

Therapy/Procedure

3	Therapeutics 05/2022 - 01/2007
1	Caloric Restriction 11/2021
1	Perinatal Care 01/2021
1	Lasers (Laser) 03/2015
1	Drug Therapy (Chemotherapy) 01/2007